Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Kutz A, Kim D,Wexler D, Liu J, Schneeweiss S, Glynn R and Patorno E
Diabetes Care 2023;46(11):2004–2014
https://doi.org/10.2337/dc23-0671
The challenges of identifying and studying type 1 diabetes in adults
ThomasJ, Jones ADiabetologia: December;2023;66: 2200 – 2212
https://doi.org/10.1007/s00125-023-06004-4
The evolving continuum of dysglycaemia: Non-diabetic hyperglycaemia in older adults
Golding J, Hope S, Chakera A and Puttana A
Diabet Med. 2023 Oct;40(10):e15177.
https://doi.org/10.1111/dme.15177
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Herold K, Gitelman S, Gottlieb P, Knetch L, Raymond R, and Ramos E
Diabetes Care. 2023 Oct 1;46(10):1848-1856
https://doi.org/10.2337/dc23-0675
Review : Incretins beyond type 2 diabetes
Mathieu Ch and Ahmadzai I
Diabetologia
https://doi.org/10.1007/s00125-023-05980-x
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Rosenstock J and Others
N Engl J Med 2023; 389:297-308
DOI: 10.1056/NEJMoa2303208
Comentarios recientes